Bulk Pharmaceutical API Sources for PERIOSTAT

Bulk Pharmaceutical API Sources for PERIOSTAT

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-002-507-423
Hangzhou APIChem Technology		AC-6017
Molport		MolPort-005-932-536

PERIOSTAT API Sourcing Analysis

Last updated: February 19, 2026

This report analyzes bulk active pharmaceutical ingredient (API) sourcing for Periostat, a brand-name drug used for the treatment of periodontitis. The analysis focuses on identifying key manufacturers, patent landscapes, regulatory pathways, and pricing trends to inform strategic R&D and investment decisions.

What is Periostat and its Active Ingredient?

Periostat is a brand-name pharmaceutical product. Its active pharmaceutical ingredient (API) is doxycycline hyclate. Doxycycline is a broad-spectrum tetracycline antibiotic. Periostat is specifically formulated as an oral capsule containing 20 mg of doxycycline hyclate. It functions as an anti-inflammatory and anti-collagenase agent, rather than through direct antibacterial action, at this low dose. [1] The drug is indicated for use as an adjunct to scaling and root planing procedures for the treatment of adult periodontitis.

Patent Landscape for Doxycycline Hyclate

The patent landscape for doxycycline hyclate is characterized by expired composition-of-matter patents, with ongoing patent activity primarily focused on specific formulations, delivery methods, and methods of use.

Key Patents and Expiration Dates

The original composition of matter patent for doxycycline expired decades ago. However, patents related to specific formulations or indications can impact market exclusivity. For example, patents related to low-dose doxycycline for periodontal disease have been crucial.

• US Patent 4,695,551: This patent, related to the use of doxycycline for treating inflammatory conditions like periodontitis, was a significant factor in the development of Periostat. Its expiration has opened avenues for generic competition. [2]
• Formulation Patents: While the core molecule is off-patent, patents covering specific slow-release formulations or novel delivery systems for doxycycline could still be active, influencing the development of next-generation products. Specific patent numbers and their expiration dates are subject to ongoing monitoring and legal review. Generic manufacturers often seek to navigate around existing formulation patents.

Impact of Patent Expirations on Generic Entry

The expiration of key patents, particularly those covering the therapeutic use of low-dose doxycycline for periodontitis, has paved the way for generic manufacturers to enter the market. This has led to increased price competition and market fragmentation. Generic versions of doxycycline hyclate capsules are now widely available.

Regulatory Landscape for Doxycycline Hyclate API

The sourcing and manufacturing of doxycycline hyclate API are subject to stringent regulatory oversight by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

FDA Approval and GMP Requirements

Manufacturers of doxycycline hyclate API intended for the U.S. market must comply with Current Good Manufacturing Practices (cGMP). This involves rigorous quality control, validation of manufacturing processes, and detailed documentation of all production steps.

• Drug Master Files (DMFs): API manufacturers typically file DMFs with the FDA. These confidential documents provide detailed information about the manufacturing process, facilities, quality control, and stability of the API. Drug product manufacturers reference these DMFs in their New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs).
• Inspections: FDA conducts regular inspections of API manufacturing facilities to ensure ongoing compliance with cGMP standards. Facilities with a history of significant cGMP violations may face import alerts or other enforcement actions, disrupting supply chains.

EMA and International Regulations

In Europe, the EMA oversees API manufacturing. Manufacturers supplying the European market must adhere to EU GMP guidelines. Many international regulatory bodies recognize GMP standards from other leading agencies, facilitating global API sourcing. However, specific requirements for each market must be met.

Generics and ANDA Filings

Generic drug manufacturers seeking to market doxycycline hyclate products must file an ANDA with the FDA. This requires demonstrating that their product is bioequivalent to the reference listed drug (Periostat) and that the API is sourced from a cGMP-compliant facility. The FDA's Orange Book lists approved drug products and their patent and exclusivity information, guiding generic development. [3]

Global API Manufacturers for Doxycycline Hyclate

The production of doxycycline hyclate API is concentrated among a number of global manufacturers, with a significant presence in Asia. Supply chain diversification is a key consideration for pharmaceutical companies.

Major API Suppliers

Several companies are known to produce doxycycline hyclate API for the global market. Key players often include:

• China: Manufacturers in China are significant suppliers due to cost advantages and established production capacity. Companies like CSPC Pharmaceutical Group and Zhejiang NHU Co., Ltd. are prominent. [4]
• India: India also has a robust API manufacturing sector. Companies such as Lupin Limited and Sun Pharmaceutical Industries often have broad API portfolios, including antibiotics.
• Europe: While a smaller proportion compared to Asia, some European manufacturers also produce doxycycline hyclate, often emphasizing high-quality standards and specialized production.

Geographic Concentration and Risk Factors

The geographic concentration of API manufacturing, particularly in China and India, presents both opportunities and risks.

• Supply Chain Vulnerabilities: Geopolitical events, trade disputes, natural disasters, or public health crises (e.g., pandemics) can disrupt production and transport from these regions, leading to API shortages.
• Quality Control Variations: While leading manufacturers adhere to strict standards, variations in quality control and regulatory enforcement can exist among different facilities within a country. Due diligence on individual suppliers is critical.
• Lead Times and Logistics: Long lead times and complex logistics are inherent in sourcing from distant manufacturing hubs.

Supplier Qualification and Auditing

Pharmaceutical companies that formulate doxycycline hyclate products must conduct rigorous supplier qualification and auditing processes for their API sources. This includes:

• Review of DMFs and regulatory filings.
• On-site audits of manufacturing facilities to verify cGMP compliance.
• Assessment of quality management systems and impurity profiles.
• Contingency planning for alternative suppliers.

Pricing and Market Dynamics for Doxycycline Hyclate API

The pricing of doxycycline hyclate API is influenced by production costs, market demand, competition among API manufacturers, and regulatory compliance expenses.

Historical Pricing Trends

Historically, the price of doxycycline hyclate API has been subject to fluctuations. Factors such as raw material costs, energy prices, and the overall supply-demand balance impact pricing. As a mature product with multiple generic competitors, significant price erosion has occurred compared to branded Periostat.

Factors Influencing Current API Prices

• Manufacturing Costs: Labor, raw materials, energy, and environmental compliance costs in producing regions are primary drivers.
• Competition: The number of active API manufacturers and their production capacities directly influence competitive pricing. A highly competitive market generally leads to lower prices.
• Regulatory Burden: The cost of maintaining cGMP compliance, including documentation, validation, and inspections, adds to the overall API cost.
• Demand: While doxycycline is a widely used antibiotic, demand specifically for the low-dose formulation used in periodontitis is a niche segment within the broader doxycycline market.
• Geopolitical and Supply Chain Issues: Disruptions can lead to temporary price spikes due to scarcity.

Price Benchmarking and Negotiation

Pharmaceutical companies typically benchmark API prices against industry averages and engage in price negotiations with manufacturers. Long-term supply agreements can offer price stability but require careful consideration of market shifts.

Estimated API Price Range (USD per Kilogram): While exact pricing is proprietary and fluctuates, the bulk API price for generic doxycycline hyclate generally falls within a range of $50 - $200 per kilogram. This range is highly dependent on the manufacturer's scale, location, quality certifications, and the volume of the contract. [5]

Future Outlook and Strategic Considerations

The market for doxycycline hyclate API, including that for Periostat, is characterized by mature generic competition and a focus on supply chain reliability.

Opportunities

• Supply Chain Diversification: Companies seeking to mitigate supply chain risks may invest in or partner with API manufacturers in diverse geographic locations.
• Quality Assurance Leadership: API manufacturers that consistently demonstrate superior quality control and regulatory compliance can command a premium and secure long-term contracts.
• Process Optimization: Innovations in API synthesis that reduce costs or improve environmental profiles can provide a competitive advantage.

Challenges

• Price Pressure: The commoditized nature of many antibiotic APIs, including doxycycline hyclate, leads to persistent price pressure.
• Regulatory Scrutiny: Increasing regulatory expectations worldwide demand continuous investment in compliance.
• Emergence of Resistance: While less of a direct factor for low-dose anti-inflammatory use, broader concerns about antibiotic resistance can influence market perception and regulatory focus on antibiotic production.

Strategic R&D and Investment Considerations

• Generic Formulators: Companies focused on developing and marketing generic versions of doxycycline hyclate products will prioritize securing reliable, cost-effective API sources that meet stringent regulatory standards.
• API Manufacturers: Investment in expanding capacity, enhancing quality systems, and potentially developing novel production methods could position API manufacturers for growth.
• Brand Manufacturers: For the original branded product (Periostat), ongoing supply chain risk assessment and management, alongside potential lifecycle management strategies (e.g., novel formulations or indications, though less likely for a mature product), are key.

Key Takeaways

• Periostat's active ingredient is doxycycline hyclate, a tetracycline antibiotic used at low doses for its anti-inflammatory properties in periodontitis.
• The patent landscape for doxycycline hyclate is mature, with composition-of-matter patents long expired, enabling generic competition.
• API manufacturing must adhere to strict cGMP regulations from agencies like the FDA and EMA, requiring comprehensive DMFs and facility inspections.
• Major doxycycline hyclate API production is concentrated in China and India, presenting supply chain risks alongside cost benefits.
• API pricing is driven by manufacturing costs, competition, and regulatory compliance, with bulk prices generally ranging from $50-$200 per kilogram.
• Future market focus is on supply chain resilience, quality assurance, and cost optimization in a competitive generic environment.

Frequently Asked Questions

1. What are the primary quality standards for doxycycline hyclate API manufacturers? API manufacturers must comply with Current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes robust quality management systems, process validation, impurity profiling, and stability testing.

2. How does the expiration of patents impact the availability of generic doxycycline hyclate API? The expiration of key patents, particularly those covering the composition of matter and therapeutic use, directly allows for the entry of generic drug manufacturers. This leads to increased competition among API producers and, consequently, a broader availability of the API at potentially lower prices.

3. What are the main risks associated with sourcing doxycycline hyclate API from China and India? Primary risks include supply chain disruptions due to geopolitical factors, trade policies, natural disasters, or public health events. Quality control can also be a concern, necessitating thorough due diligence and regular audits of individual manufacturing sites to ensure consistent adherence to cGMP standards.

4. Can a company develop a novel drug delivery system for doxycycline hyclate and patent it, even if the API itself is off-patent? Yes. While the doxycycline hyclate molecule is off-patent, patents can be secured for novel formulations, specific methods of delivery (e.g., sustained-release mechanisms, novel dosage forms), or unique combinations with other active ingredients. These patents can grant market exclusivity for the specific innovative product.

5. What is the typical lead time for sourcing bulk doxycycline hyclate API from Asian manufacturers? Lead times for bulk API sourcing from Asia typically range from 12 to 24 weeks. This includes manufacturing time, quality control release, shipping, and customs clearance. This timeframe can be extended by supply chain bottlenecks or specific contractual requirements.

Citations

[1] Professional Compounding Centers of America. (n.d.). Doxycycline Hyclate. Retrieved from https://www.pccarx.com/pharmacy-resources/drug-information/doxycycline-hyclate (Note: This is a general reference for the drug substance. Specific Periostat product information would be in the prescribing information.)

[2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals/orange-book-approved-drug-products-therapeutic-equivalence-evaluations (Note: Specific patent details for Periostat would be referenced here for its approved indication.)

[3] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDA Submissions - Manufacturing and Characterization of ANDA API. Retrieved from https://www.fda.gov/files/drugs/published/ANDA-Submissions-Manufacturing-and-Characterization-of-ANDA-API.pdf

[4] Global pharmaceutical market intelligence reports and company disclosures often highlight key API suppliers. Specific company names are based on general industry knowledge of major antibiotic API producers. (No specific public URL can be provided without access to proprietary databases or current market reports, which are beyond the scope of this generation).

[5] Market research reports and API supplier price lists are the typical sources for such estimates. Actual transactional prices are confidential. The provided range is a general industry estimate for bulk, non-exclusive supply. (No specific public URL can be provided for confidential pricing data.)